Paxmedica to present at the h.c. wainwright 25th annual global investment conference

Presentation on tuesday, september 12, 2023 at 3:00pm edt tarrytown, ny, aug. 30, 2023 (globe newswire) -- via newmediawire -- paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd) and other serious conditions with intractable neurologic symptoms, today announced that it will present at the h.c. wainwright 25th annual global investment conference, which is scheduled to take place september 11 – 13, 2023, in new york, ny.
PXMD Ratings Summary
PXMD Quant Ranking